These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 21568893)
1. Pharmacophore modelling: a forty year old approach and its modern synergies. Caporuscio F; Tafi A Curr Med Chem; 2011; 18(17):2543-53. PubMed ID: 21568893 [TBL] [Abstract][Full Text] [Related]
2. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification. Islam MA; Pillay TS J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527 [TBL] [Abstract][Full Text] [Related]
3. Pharmacophore based drug design approach as a practical process in drug discovery. Gao Q; Yang L; Zhu Y Curr Comput Aided Drug Des; 2010 Mar; 6(1):37-49. PubMed ID: 20370694 [TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Yang SY Drug Discov Today; 2010 Jun; 15(11-12):444-50. PubMed ID: 20362693 [TBL] [Abstract][Full Text] [Related]
5. Receptor-based pharmacophore tool for design and development of next-generation drugs. Udayakumar M; Kumar PS; Hemavathi K; Shanmugapriya P; Seenivasagam R Int J Bioinform Res Appl; 2013; 9(5):487-516. PubMed ID: 24001724 [TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Potential gp120 of HIV-1 Antagonist Using Per-Residue Energy Contribution-Based Pharmacophore modelling. Berinyuy E; Soliman MES Interdiscip Sci; 2017 Sep; 9(3):406-418. PubMed ID: 27165479 [TBL] [Abstract][Full Text] [Related]
7. New features that improve the pharmacophore tools from Accelrys. Sutter J; Li J; Maynard AJ; Goupil A; Luu T; Nadassy K Curr Comput Aided Drug Des; 2011 Sep; 7(3):173-80. PubMed ID: 21726193 [TBL] [Abstract][Full Text] [Related]
8. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation. Halder AK; Saha A; Saha KD; Jha T J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685 [TBL] [Abstract][Full Text] [Related]
9. Computational Evaluation of HIV-1 gp120 Conformations of Soluble Trimeric gp140 Structures as Targets for de Novo Docking of First- and Second-Generation Small-Molecule CD4 Mimics. Moraca F; Acharya K; Melillo B; Smith AB; Chaiken I; Abrams CF J Chem Inf Model; 2016 Oct; 56(10):2069-2079. PubMed ID: 27602436 [TBL] [Abstract][Full Text] [Related]
10. The Development of Pharmacophore Modeling: Generation and Recent Applications in Drug Discovery. Lu X; Yang H; Chen Y; Li Q; He SY; Jiang X; Feng F; Qu W; Sun H Curr Pharm Des; 2018; 24(29):3424-3439. PubMed ID: 30101699 [TBL] [Abstract][Full Text] [Related]
11. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations. Saxena S; Abdullah M; Sriram D; Guruprasad L J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866 [TBL] [Abstract][Full Text] [Related]
12. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach. Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998 [TBL] [Abstract][Full Text] [Related]